文献速递介入腹部胸部US

超声引导微波消融与放射性碘-125粒子植入治疗胸腹壁种植性肿瘤的疗效比较研究

Therapeutic outcomes of ultrasound-guided microwave ablation and radioactive iodine-125 seed implantation for thoracoabdominal wall seeding tumours: a comparative study.
PubMed 文献 · Clin Radiol · 2026-02-12

回顾性分析93例胸腹壁种植性肿瘤患者,比较微波消融(MWA,n=66)与放射性碘-125粒子植入(RISI,n=27)的疗效与安全性。MWA组局部肿瘤进展率(30.3% vs 51.9%,P=0.050)和死亡率(33.3% vs 59.3%,P=0.021)显著低于RISI组;MWA在局部无复发生存(HR 0.499,95%CI 0.251-0.992,P=0.04)和总生存(HR 0.437,95%CI 0.227-0.838,P=0.01)方面优于RISI。两组并发症发生率无显著差异(31.8% vs 14.8%,P=0.093)。

要点

  • MWA组局部肿瘤进展率30.3% vs RISI组51.9%(P=0.050),死亡率33.3% vs 59.3%(P=0.021)。
  • MWA较RISI改善局部无复发生存(HR 0.499,95%CI 0.251-0.992,P=0.04)和总生存(HR 0.437,95%CI 0.227-0.838,P=0.01)。
  • MWA组辅助技术使用率90.1% vs RISI组11.1%(P<0.001),并发症发生率两组无显著差异(31.8% vs 14.8%,P=0.093)。

核心结论

  • 在胸腹壁种植性肿瘤患者中,MWA较RISI获得更好的肿瘤控制、更高的辅助技术使用率,且并发症相当。

研究设计与样本

  • 回顾性分析93例胸腹壁种植性肿瘤患者,接受MWA治疗66例、RISI治疗27例,比较两组局部肿瘤进展、局部无复发生存、总生存和并发症发生率。

诊断标准与关键数值

  • MWA组中位随访36.0个月,RISI组中位随访24.8个月。
  • MWA组局部肿瘤进展率30.3% vs RISI组51.9%(P=0.050),死亡率33.3% vs 59.3%(P=0.021)。
  • MWA较RISI的局部无复发生存HR 0.499(95%CI 0.251-0.992,P=0.04),总生存HR 0.437(95%CI 0.227-0.838,P=0.01)。
  • 亚组分析显示内腹壁亚组局部无复发生存发生率更高(P<0.001),SAW亚组总生存更高(P=0.039);肿瘤≤4 cm亚组局部无复发生存发生率更高(P=0.012),>4 cm亚组总生存更高(P=0.034)。
  • 多因素分析中MWA为总生存的独立保护因素,但对局部无复发生存不是独立保护因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: The aim of this study was to compare the therapeutic outcomes and safety of microwave ablation (MWA) with radioactive iodine-125 seed implantation (RISI) for the treatment of thoracoabdominal wall seeding tumours (TAWSTs).

MATERIALS AND METHODS: A retrospective analysis of 93 TAWST patients treated with MWA (n=66) or RISI (n=27) was performed. We compared the local tumour progression (LTP), local recurrence-free survival (LRFS), overall survival (OS), and complication rates between the two groups.

RESULTS: The median follow-up time was 36.0 months in the MWA group and 24.8 months in the RISI group. The LTP rate (30.3% vs 51.9 %, P=0.050) and mortality rate (33.3% vs 59.3%, P=0.021) in the MWA group were significantly lower than those in the RISI group. In TAWST patients, MWA was superior to RISI in terms of LRFS (hazard ratio [HR]: 0.499, 95% confidence interval [CI]: 0.251-0.992, P=0.04) and OS (HR: 0.437, 95% CI: 0.227-0.838, P=0.01). The subgroup analysis revealed higher incidences of LRFS for the inner abdominal wall (IAW) subgroup (P<0.001) and OS for the SAW subgroup (P=0.039). Similarly, in a subgroup analysis based on tumour size, MWA was associated with a greater incidence of LRFS in the ≤4-cm subgroup (P=0.012) and OS in the >4-cm subgroup (P=0.034). In the multivariate analysis, MWA was an independent protective factor for OS but not for LRFS. In addition, the use of assistive technologies in the MWA group was significantly greater than that in the RISI group (90.1% vs 11.1%, P<0.001). There were no significant differences between the two groups regarding complications (31.8% vs 14.8%, P=0.093).

CONCLUSION: In patients with TAWST, MWA resulted in better tumour control, a greater assistive technology utilisation rate, and comparable complications than RISI.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Li L, Qi E, Dong G, et al. Therapeutic outcomes of ultrasound-guided microwave ablation and radioactive iodine-125 seed implantation for thoracoabdominal wall seeding tumours: a comparative study. Clin Radiol. 2026. PMID: 41849927. doi:10.1016/j.crad.2026.107264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。